Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013113791> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2013113791 endingPage "335" @default.
- W2013113791 startingPage "329" @default.
- W2013113791 abstract "Abstract Aims This 24‐week, randomized, multicentre, open‐label, parallel‐group clinical trial compared efficacy and safety of repaglinide monotherapy, rosiglitazone monotherapy, and combination therapy (repaglinide plus rosiglitazone) in Type 2 diabetes after unsatisfactory response to sulphonylurea or metformin monotherapy. Methods Enrolled patients ( n = 252) were adults having Type 2 diabetes for at least 1 year, with HbA 1c values > 7.0% after previous monotherapy (sulphonylurea or metformin, ≥ 50% maximal dose). Prior therapy was withdrawn for 2 weeks, followed by randomization to repaglinide, rosiglitazone, or repaglinide/rosiglitazone. Study treatments were initiated with a 12‐week dose optimization period (doses optimized according to labelling), followed by a 12‐week maintenance period. Efficacy endpoints were changes in HbA 1c values (primary) or fasting plasma glucose values (secondary). Results Baseline HbA 1c values were comparable (9.3% for repaglinide, 9.0% for rosiglitazone, 9.1% for combination). Mean changes in HbA 1c values at the end of treatment were greater for repaglinide/rosiglitazone therapy (−1.43%) than for repaglinide (−0.17%) or rosiglitazone (−0.56%) monotherapy. Reductions of fasting plasma glucose values were also greater for combination therapy (−5.2 mmol/l, −94 mg/dl) than for repaglinide monotherapy (−3.0 mmol/l, −54 mg/dl) or rosiglitazone monotherapy (−3.7 mmol/l, −67 mg/dl). Minor hypoglycaemic events occurred in 9% of combination therapy patients, vs. 6% for repaglinide and 2% for rosiglitazone. Individual weight gains for combination therapy were correlated to HbA 1c response. Conclusions The combination therapy regimen was well tolerated. In patients previously showing unsatisfactory response to oral monotherapy, glycaemic reductions were greater for the repaglinide/rosiglitazone combination regimen than for use of either repaglinide or rosiglitazone alone." @default.
- W2013113791 created "2016-06-24" @default.
- W2013113791 creator A5015275535 @default.
- W2013113791 creator A5023487929 @default.
- W2013113791 creator A5050076657 @default.
- W2013113791 creator A5053691497 @default.
- W2013113791 creator A5058109645 @default.
- W2013113791 creator A5074472432 @default.
- W2013113791 creator A5077292989 @default.
- W2013113791 date "2004-02-20" @default.
- W2013113791 modified "2023-10-15" @default.
- W2013113791 title "Combination therapy for Type 2 diabetes: repaglinide plus rosiglitazone" @default.
- W2013113791 cites W1969061933 @default.
- W2013113791 cites W1988474859 @default.
- W2013113791 cites W1993034883 @default.
- W2013113791 cites W2043316108 @default.
- W2013113791 cites W2095916401 @default.
- W2013113791 cites W2113317508 @default.
- W2013113791 cites W2169005776 @default.
- W2013113791 cites W2188846692 @default.
- W2013113791 cites W2337454357 @default.
- W2013113791 cites W2581706353 @default.
- W2013113791 doi "https://doi.org/10.1111/j.1464-5491.2004.01143.x" @default.
- W2013113791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15049934" @default.
- W2013113791 hasPublicationYear "2004" @default.
- W2013113791 type Work @default.
- W2013113791 sameAs 2013113791 @default.
- W2013113791 citedByCount "34" @default.
- W2013113791 countsByYear W20131137912012 @default.
- W2013113791 countsByYear W20131137912016 @default.
- W2013113791 crossrefType "journal-article" @default.
- W2013113791 hasAuthorship W2013113791A5015275535 @default.
- W2013113791 hasAuthorship W2013113791A5023487929 @default.
- W2013113791 hasAuthorship W2013113791A5050076657 @default.
- W2013113791 hasAuthorship W2013113791A5053691497 @default.
- W2013113791 hasAuthorship W2013113791A5058109645 @default.
- W2013113791 hasAuthorship W2013113791A5074472432 @default.
- W2013113791 hasAuthorship W2013113791A5077292989 @default.
- W2013113791 hasConcept C126322002 @default.
- W2013113791 hasConcept C134018914 @default.
- W2013113791 hasConcept C2776999253 @default.
- W2013113791 hasConcept C2777180221 @default.
- W2013113791 hasConcept C2778384471 @default.
- W2013113791 hasConcept C2779463123 @default.
- W2013113791 hasConcept C2780152017 @default.
- W2013113791 hasConcept C2780323712 @default.
- W2013113791 hasConcept C2781281211 @default.
- W2013113791 hasConcept C2781413609 @default.
- W2013113791 hasConcept C555293320 @default.
- W2013113791 hasConcept C71924100 @default.
- W2013113791 hasConcept C90924648 @default.
- W2013113791 hasConcept C98274493 @default.
- W2013113791 hasConceptScore W2013113791C126322002 @default.
- W2013113791 hasConceptScore W2013113791C134018914 @default.
- W2013113791 hasConceptScore W2013113791C2776999253 @default.
- W2013113791 hasConceptScore W2013113791C2777180221 @default.
- W2013113791 hasConceptScore W2013113791C2778384471 @default.
- W2013113791 hasConceptScore W2013113791C2779463123 @default.
- W2013113791 hasConceptScore W2013113791C2780152017 @default.
- W2013113791 hasConceptScore W2013113791C2780323712 @default.
- W2013113791 hasConceptScore W2013113791C2781281211 @default.
- W2013113791 hasConceptScore W2013113791C2781413609 @default.
- W2013113791 hasConceptScore W2013113791C555293320 @default.
- W2013113791 hasConceptScore W2013113791C71924100 @default.
- W2013113791 hasConceptScore W2013113791C90924648 @default.
- W2013113791 hasConceptScore W2013113791C98274493 @default.
- W2013113791 hasIssue "4" @default.
- W2013113791 hasLocation W20131137911 @default.
- W2013113791 hasLocation W20131137912 @default.
- W2013113791 hasOpenAccess W2013113791 @default.
- W2013113791 hasPrimaryLocation W20131137911 @default.
- W2013113791 hasRelatedWork W1686022845 @default.
- W2013113791 hasRelatedWork W1986535499 @default.
- W2013113791 hasRelatedWork W2013113791 @default.
- W2013113791 hasRelatedWork W2172062051 @default.
- W2013113791 hasRelatedWork W2234493322 @default.
- W2013113791 hasRelatedWork W2354249222 @default.
- W2013113791 hasRelatedWork W2390190321 @default.
- W2013113791 hasRelatedWork W2391046224 @default.
- W2013113791 hasRelatedWork W3029800468 @default.
- W2013113791 hasRelatedWork W4248476366 @default.
- W2013113791 hasVolume "21" @default.
- W2013113791 isParatext "false" @default.
- W2013113791 isRetracted "false" @default.
- W2013113791 magId "2013113791" @default.
- W2013113791 workType "article" @default.